Tempus AI (NASDAQ:TEM) Director David Epstein Sells 370 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of Tempus AI stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $90.00, for a total value of $33,300.00. Following the completion of the sale, the director directly owned 26,671 shares in the company, valued at approximately $2,400,390. This represents a 1.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Tempus AI Price Performance

NASDAQ:TEM opened at $82.26 on Thursday. The company has a market cap of $14.29 billion, a P/E ratio of -69.13 and a beta of 4.86. Tempus AI, Inc. has a 52-week low of $31.36 and a 52-week high of $104.32. The stock’s 50-day simple moving average is $86.02 and its 200 day simple moving average is $70.60. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The business had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 95.20%. The firm’s revenue for the quarter was up 84.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.46) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Guggenheim boosted their price target on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, September 26th. TD Cowen downgraded Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price target on the stock. in a research report on Tuesday, October 21st. Canaccord Genuity Group decreased their target price on Tempus AI from $110.00 to $95.00 and set a “buy” rating on the stock in a report on Wednesday. Needham & Company LLC boosted their target price on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $80.54.

Institutional Trading of Tempus AI

Several large investors have recently made changes to their positions in the company. ARK Investment Management LLC boosted its holdings in shares of Tempus AI by 35.9% in the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company’s stock valued at $361,867,000 after purchasing an additional 1,981,755 shares in the last quarter. Vanguard Group Inc. boosted its stake in Tempus AI by 6,247.5% in the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock valued at $289,204,000 after buying an additional 5,900,668 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its stake in shares of Tempus AI by 31.5% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company’s stock valued at $205,401,000 after purchasing an additional 1,021,460 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Tempus AI in the second quarter valued at approximately $54,020,000. Finally, CloudAlpha Capital Management Limited Hong Kong acquired a new position in shares of Tempus AI during the first quarter worth $34,119,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.